➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
AstraZeneca
Medtronic
Merck

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

Litigation Details for City of Providence, Rhode Island v. Merck & Co., Inc. (D. Mass. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

City of Providence, Rhode Island v. Merck & Co., Inc. (D. Mass. 2018)

Docket   Get Started for $10 Date Filed 2018-03-15
Court District Court, D. Massachusetts Date Terminated 2018-06-18
Cause 28:1332 Diversity-Other Contract Assigned To Rya Weickert Zobel
Jury Demand Plaintiff Referred To
Parties CITY OF PROVIDENCE, RHODE ISLAND; GLENMARK GENERICS INC., U.S.A.; GLENMARK PHARMACEUTICALS, LTD.; MERCK & CO., INC.; MERCK SHARP & DOHME CORP.; MSP SINGAPORE CO. LLC; SCHERING CORP.; SCHERING-PLOUGH CORP.
Patents 7,030,106; 7,612,058; RE37,336; RE37,343; RE37,721; RE42,208; RE42,353; RE42,461
Attorneys Christopher D. Dusseault; Michael M. Lee; Natashia Tidwell; Nathaniel L. Orenstein; Noah J. Kaufman; Samuel G. Liversidge; Todd A Seaver; William H. Kettlewell
Firms Berman Tabacco; Gibson Dunn & Crutcher; Hogan Lovells US LLP; Morgan, Lewis & Bockius LLP
Link to Docket External link to docket
Small Molecule Drugs cited in City of Providence, Rhode Island v. Merck & Co., Inc.
The small molecule drugs covered by the patents cited in this case are   Get Started for $10 ,   Get Started for $10 ,   Get Started for $10 , and   Get Started for $10 .
Biologic Drugs cited in City of Providence, Rhode Island v. Merck & Co., Inc.

The biologic drugs covered by the patents cited in this case are   Get Started for $10 ,   Get Started for $10 ,   Get Started for $10 ,   Get Started for $10 ,   Get Started for $10 , and   Get Started for $10 .

Details for City of Providence, Rhode Island v. Merck & Co., Inc. (D. Mass. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-03-15 1 as U.S. Patent No. 7,030,106. The ’106 patent was Merck’s first sterol non-absorption patent. It has …azetidinone patents include the ’365 patent, the ’115 patent, the ’966 patent, the RE’721 patent, and the…three patents for these discoveries (one reissued as U.S. Patent No. RE37,721 (the “RE’721 patent”)). … 5. Patents are not bulletproof. 40. Patents are not bulletproof. Patents are routinely… A patent is also invalid or unenforceable when a later acquired patent is not patentably distinct External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Merck
McKesson
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.